EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

 

CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting. Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASCO 2020.

 

 

You can see the ASCO20 virtual agenda and abstracts here. All presentations will be available on the ASCO20 website for a period of 180-days.

 







Recent news

» EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myeloma

» EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myeloma

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.